As Pfizer navigates these challenges, it faces rising competition from agile biotech firms wielding AI, gene editing, and mRNA technologies. By 2030, these innovators could surpass Pfizer’s drug ...

Pfizer recently made headlines with a strategic collaboration with Guardant Health, aimed at enhancing its oncology portfolio through advanced liquid biopsy technology. Simultaneously, the company ...

Pfizer has a very low valuation and a sky-high dividend yield. But this could be a broken stock, not so much a broken company. Pfizer's product sales could churn as patents expire, but the stock ...

Pfizer's (NYSE: PFE) share price has fallen more than the S&P 500 so far this year. The big pharma stock is nearly 60% below its high set in late 2022. By most standards, Pfizer looks like the ...

Pfizer decided to discontinue the development of its leading weight management candidate. Despite this setback, the company has a deep pipeline of candidates, especially in oncology. Pfizer's ...